Navigation Links
Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder
Date:5/26/2010

e using the total PEC score.  In each study, change from baseline for each of the five items comprising the total PEC score (hostility, uncooperativeness, excitement, poor impulse control and tension, each scored 1-7) was determined starting at 10 minutes post-dose.  In addition, patients were grouped by baseline severity of agitation (median split) using the total PEC scores for each study and response rates for the higher and lower agitation populations were compared.

Each of the five items comprising the PEC scale improved with AZ-004 treatment, with differences from placebo starting at 10 minutes after dosing.  On average, each item improved 1 to 2 units from baseline over the first two hours post-dose for both patient groups.  Thus, the change in total PEC score observed with Staccato loxapine treatment derives from similar changes on each of the five items assessed.  The median PEC score at baseline was 17 across the two studies.  For the 10 mg dose groups and patients having a total PEC score of 17 or less at baseline, there was on average a total PEC score improvement of 8.3 and 8.5 units for patients with schizophrenia and bipolar disorder, respectively.  For patients having a total PEC score of higher than 17 at baseline, there was on average a total PEC score improvement of 8.9 and 9.7 units for patients with schizophrenia and bipolar disorder, respectively.  

About the AZ-004 Cardiovascular Safety Studies

The cardiovascular safety of Staccato loxapine was assessed in a Phase 1 study of 32 subjects taking chronic antipsychotic medication and in a thorough QT study (TQT) in 48 healthy volunteers.  These results were presented in the poster presentation, "The Cardiovascular Safety of Inhaled Loxapine (AZ-004)" (Poster Session 6).

The Phase 1 study was a double-blind
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.; Biovail Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
2. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
3. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
7. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
10. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
11. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... VIENNA , July 29, 2014 ... Vienna, Austria will present data from a ... that aims to slow or stop Parkinson,s disease progression. ... a $ 1.5 million grant and will discuss the impact ... community. When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... 2014   Abide Therapeutics announced today ... its board of directors. Thornberry was previously senior ... for Merck & Co. Inc., where she led ... in diabetes, osteoporosis, fertility and contraception. Thornberry, a ... that resulted in the discovery of Januvia TM ...
(Date:7/29/2014)... Today, Frost & Sullivan recognizes Validic ... Practices Award for Customer Value Leadership. The Validic ... connects digital health application developers, medical devices and ... prevention and wellness companies, population health management companies ... Frost & Sullivan presents this award to a ...
Breaking Medicine Technology:Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
(Date:7/29/2014)... Some people can handle stressful situations better than ... Even identical twins show differences in how they ... pattern in the brains of genetically identical mice ... in stressful situations. , The findings, published ... eventually help researchers prevent potential consequences of chronic ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a ... Studies show that over 400 hospitals probably won’t survive ... tool that great hospitals use to survive the threat ... Their secret? Debriefing - the simple process of systematically ... an operational event. Debriefing is a standard procedure in ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... live an average three years longer than people who don,t run, ... this study is that it appears that you can reap this ... every day, the 15-year study suggests. "People may not ... author Duck-chul Lee, an assistant professor of kinesiology at Iowa State ...
Breaking Medicine News(10 mins):Health News:A new brain-based marker of stress susceptibility 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3
... Dr. Neil Kurtz Resigns as President and Chief Executive Officer; ... Graham Appointed Acting Chief Executive Officer -, LA ... ) today announced that Neil Kurtz, M.D., is,resigning as President, ... of August 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume ...
... genetic variation , , FRIDAY, Aug. 8 (HealthDay News) -- A ... salt intake and high blood pressure. , The study, which ... possible genetic factor that might make people more or less ... -- variants of a gene for angiotensinogen, a molecule that ...
... polar opposite diseases, but both depend upon dopamine in ... drug addicts get too much of it. Although the ... known, the way it works has been a mystery. ... Medicine has revealed that dopamine strengthens and weakens the ...
... release is available in French . , ... that patients who receive early treatment for Hepatitis C ... develop a rapid poly-functional immune response against HCV similar ... new study published in the Journal of Virology ...
... Delayed diagnosis, less successful surgery, pair of studies finds , , ... for prostate cancer may not be accurate for obese men, ... less likely to be effective for them, a new pair ... be diagnosed with an aggressive form of the disease," said ...
... in Senior Housing Growing; Adoption of Healthy Lifestyle ... ... the face of conventional,wisdom, which has long proven true, women live longer ... than ever are moving,into senior living residences nationwide. Historically female-dominated,senior living communities ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Too Much Salt Boosts Blood Pressure 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 3Health News:Early treatment is key to combating hepatitis C virus 2Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:More Men Moving Into Senior Residences 2Health News:More Men Moving Into Senior Residences 3
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
12" suture passer...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: